Friday, November 22

Tag: Obesity

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?
27Dec By adminNo Comments
Money

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

In pharma, you can take a larger slice of the healthcare pie than your peers, but you are still constrained by the size of the pie. No matter how good your cancer or diabetes drug is, healthcare systems will still have to keep paying for heart disease and rheumatoid arthritis treatments too.That, in a nutshell, is why the divergence of obesity-diabetes companies from the rest of the industry in recent years can’t go on forever. In 2023, Eli Lilly and Novo Nordisk have risen more than 50% each, to become the two largest pharma companies by market capitalization, with their combined value now hovering around $1 trillion. By comparison, the rest of the industry badly underperformed the market, with the NYSE Arca Pharmaceutical Index rising a measly 4% compared with 24% for the S&P 500.  ...
Read More
Health experts say obese children should receive at least 26 hours of intensive counseling every year
17Dec By adminNo Comments
Health

Health experts say obese children should receive at least 26 hours of intensive counseling every year

Health experts: Obese children should receive at least 26 hours of intensive counseling every year Health experts: Obese children should receive at least 26 hours of intensive counseling every year 02:03 TEANECK, N.J. -- New guidance from some health experts is taking an aggressive stand on curbing childhood obesity.The recommendations say doctors need to intervene in some cases.CBS New York has been talking with doctors about the crisis. "It's a ver...
Read More
Obesity Drugs Put These Stocks on a Crash Diet—Now They’re Rebounding
17Nov By adminNo Comments
Money

Obesity Drugs Put These Stocks on a Crash Diet—Now They’re Rebounding

Updated Nov. 17, 2023 10:54 am ETThere is a bit of cognitive dissonance in healthcare investing right now.After reviewing the highly anticipated results from a study of Novo Nordisk’s blockbuster obesity treatment Wegovy released over the weekend, cardiologists at a major medical meeting and the pharma crowd on Wall Street were broadly upbeat. “Today’s confirmatory results lay the groundwork for the coming paradigm shift of metabolic treatment,” gushed Evan Seigerman, an analyst at BMO Capital Markets.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Obesity Drugs Put These Stocks on a Crash Diet—Now They’re Rebounding
17Nov By adminNo Comments
World

Obesity Drugs Put These Stocks on a Crash Diet—Now They’re Rebounding

There is a bit of cognitive dissonance in healthcare investing right now.After reviewing the highly anticipated results from a study of Novo Nordisk’s blockbuster obesity treatment Wegovy released over the weekend, cardiologists at a major medical meeting and the pharma crowd on Wall Street were broadly upbeat. “Today’s confirmatory results lay the groundwork for the coming paradigm shift of metabolic treatment,” gushed Evan Seigerman, an analyst at BMO Capital Markets.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
FDA approves new weight loss drug Zepbound
9Nov By adminNo Comments
Health

FDA approves new weight loss drug Zepbound

FDA approves new weight loss drug Zepbound - CBS News Watch CBS News The Food and Drug Administration has approved the diabetes drug Mounjaro, which will be marketed as a weight loss drug under the name Zepbound. Be the first to know Get browser notifications for breaking news, live events, and exclusive reporting. Not Now Turn On
Read More
Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.
8Nov By adminNo Comments
World

Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.

Updated Nov. 8, 2023 1:01 pm ETU.S. drug regulators have approved expanding the use of Eli Lilly’s diabetes drug Mounjaro to include the treatment of obesity.The Food and Drug Administration’s decision Wednesday furthers the rapid rise of Mounjaro—and similar-acting therapies Ozempic and Wegovy from Novo Nordisk—that have in a matter of months reshaped the treatment of obesity and doctors’ understanding of its roots.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Obesity Drug Demand Outstrips Supply
3Nov By adminNo Comments
Money

Obesity Drug Demand Outstrips Supply

Eli Lilly’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as an obesity treatment before the end of the year, which would lead to a surge in demand. Whether there will be enough of the drug is a different question. Both Lilly and its competitor, Denmark’s Novo Nordisk, which makes Ozempic and its sister drug Wegovy, are struggling to meet skyrocketing demand for their medications. There is no quick fix for that given the complexity of building out manufacturing capacity for the injections. Both companies are investing billions of dollars a year to try to catch up.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
The ‘Ozempic Effect’ on Wall Street Has Gone Overboard
1Nov By adminNo Comments
World

The ‘Ozempic Effect’ on Wall Street Has Gone Overboard

Updated Nov. 1, 2023 4:39 pm ETAmerica leads developed nations when it comes to obesity. Those paying close attention to the stock market and recent corporate earnings calls might be forgiven for thinking the problem has been solved.Call it the Ozempic effect. A new generation of highly effective weight-loss and diabetes drugs known as GLP-1s has led to fanciful assumptions on Wall Street that spell doom for companies that have profited from America’s obesity problem. It has also led to speculation that gigantic opportunities await those that would benefit from the aggregate weight loss.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Never Mind Covid, Investors Want a Pfizer Obesity Pill
31Oct By adminNo Comments
Money

Never Mind Covid, Investors Want a Pfizer Obesity Pill

Some of this year’s best performers in the healthcare sector are companies expected to profit from the anti-obesity drug craze, with Eli Lilly and Novo Nordisk shares both up more than 40% each. Much of the rest of the industry is underwater, with some of the biggest decliners being pandemic winners such as Pfizer and Moderna.It is little wonder, then, that investors were hoping Pfizer could jump to the winning camp with an obesity pill. But the company’s silence on its experimental oral medication, danuglipron, during its earnings release Tuesday, is worrying Wall Street. “Not one mention [of danuglipron] in the prepared remarks from Pfizer,” noted Will Sevush, a healthcare strategist for Jefferies. Before today’s earnings, David Risinger, a Leerink Partners analyst, had written that Pfi...
Read More